Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium™ 2020

CRANBURY, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel...
January 13, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance

2020 Galafold Revenue Guidance of $250M-$260M Focused on Pompe Phase 3 PROPEL study and manufacturing to support 2021 BLA and MAA Continued Progress Across Industry Leading Rare Disease Gene...
January 09, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance

Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations...
January 07, 2020 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease

123 Patients Enrolled in Phase 3 PROPEL Study – Enrollment Completed in 4Q2019 Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition...
November 11, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates

3Q19 Galafold® (migalastat) Revenue of $48.8M and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M ...
October 30, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019

CRANBURY, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019...
October 24, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society

New Data Support Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years...
October 10, 2019 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day

Analyst Day 2019 to Highlight Financial Outlook andRobust Portfolio of Novel Therapies for Rare Metabolic Diseases 3Q19 Galafold® (migalastat) Preliminary Unaudited Revenue of ~$48M+ and 1,000+...
October 02, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society

Persistent and Durable Responses Across Safety, Functional Outcomes and Biomarkers for ERT-Naïve and ERT-Switch Patients in Cohorts 1, 2 and 3 Out to Month 24 Data in Additional Switch Patients...
October 01, 2019 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019

CRANBURY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming...